Literature DB >> 26149027

Life after acquired thrombotic thrombocytopenic purpura: morbidity, mortality, and risks during pregnancy.

S K Vesely1.   

Abstract

Patients who have recovered from their acute episode of acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) were once thought to have complete recovery except for risk of relapse. Data from previous publications from the Oklahoma TTP-hemolytic uremic syndrome (HUS) Registry are summarized. Patients have decreased cognitive function and increased prevalence of hypertension, systemic lupus erythematosus, major depression, and albuminuria as compared to the expected values from the US population. The proportion of patients that died during the follow-up period was greater than expected based on the US population reference population. Among women who had a pregnancy following recovery from TTP, relapse during pregnancy or postpartum is uncommon, but the occurrence of preeclampsia may be increased. Thirteen of 16 pregnancies in these women resulted in healthy children. Increased morbidity and mortality in TTP patients following recovery suggest that TTP may be more of a chronic disorder than a disorder with acute episodes and complete recovery.
© 2015 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  ADAMTS13 protein, human; mortality; outcomes assessment; pregnancy; thrombotic thrombocytopenic purpura

Mesh:

Substances:

Year:  2015        PMID: 26149027     DOI: 10.1111/jth.12953

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  6 in total

1.  Atypical presentations of thrombotic thrombocytopenic purpura: a diagnostic role for ADAMTS13.

Authors:  Yosef Kalish; Amihai Rottenstreich; Deborah Rund; Sarit Hochberg-Klein
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

2.  Maternal and fetal outcomes of pregnancy occurring after a diagnosis of immune-mediated thrombotic thrombocytopenic purpura.

Authors:  Jenna Brown; Bindu Potugari; Marshall A Mazepa; Ruhail Kohli; Alison R Moliterno; Robert A Brodsky; Jason A Vaught; Richard Burwick; Shruti Chaturvedi
Journal:  Ann Hematol       Date:  2022-08-06       Impact factor: 4.030

Review 3.  Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes.

Authors:  Selin Kucukyurt; Ahmet Emre Eskazan
Journal:  J Blood Med       Date:  2020-09-28

4.  Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study.

Authors:  Wolfgang Miesbach; Jan Menne; Martin Bommer; Ulf Schönermarck; Thorsten Feldkamp; Martin Nitschke; Timm H Westhoff; Felix S Seibert; Rainer Woitas; Rui Sousa; Michael Wolf; Stefan Walzer; Björn Schwander
Journal:  Orphanet J Rare Dis       Date:  2019-11-15       Impact factor: 4.123

5.  Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study.

Authors:  Paul Knoebl; Spero Cataland; Flora Peyvandi; Paul Coppo; Marie Scully; Johanna A Kremer Hovinga; Ara Metjian; Javier de la Rubia; Katerina Pavenski; Jessica Minkue Mi Edou; Hilde De Winter; Filip Callewaert
Journal:  J Thromb Haemost       Date:  2019-12-09       Impact factor: 5.824

Review 6.  TTP: From empiricism for an enigmatic disease to targeted molecular therapies.

Authors:  Nuno A G Graça; Bérangère S Joly; Jan Voorberg; Karen Vanhoorelbeke; Nicolas Béranger; Agnès Veyradier; Paul Coppo
Journal:  Br J Haematol       Date:  2022-02-10       Impact factor: 8.615

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.